Diabetes mellitus (DM) is a group of chronic metabolic disorders defined by persistent hyperglycaemia resulting from defects in insulin secretion, insulin action, or both [1,2]. It has become one of the most pressing global public-health challenges of the twenty-first century. The International Diabetes Federation estimated that 589 million adults aged 20–79 years were living with diabetes in 2024, equivalent to about one in nine adults, with the figure projected to reach 853 million by 2050; diabetes was responsible for approximately 3.4 million deaths in 2024 [1]. This escalating burden reflects population ageing, urbanisation, physical inactivity, and rising obesity.

Diabetes is broadly classified into type 1 (T1DM), which results from autoimmune destruction of pancreatic β-cells leading to absolute insulin deficiency, and type 2 (T2DM), which accounts for roughly 90–95% of cases and arises from insulin resistance combined with a relative insulinopenia [2,3]. Gestational diabetes and specific genetic or secondary forms constitute the remaining categories. Diagnosis relies on standardised biochemical thresholds: a fasting plasma glucose ≥126 mg/dL, a 2-hour post-load glucose ≥200 mg/dL, an HbA1c ≥6.5%, or a random glucose ≥200 mg/dL in a symptomatic individual [2].

At the biochemical level, insulin is the principal anabolic hormone governing fuel homeostasis. Binding of insulin to its receptor triggers autophosphorylation and activation of the insulin-receptor substrate/phosphatidylinositol-3-kinase/Akt cascade, promoting translocation of GLUT4 to the plasma membrane, glucose uptake in muscle and adipose tissue, glycogenesis, lipogenesis, and suppression of hepatic gluconeogenesis [4]. In T2DM, impaired signalling at multiple nodes reduces peripheral glucose disposal, disinhibits hepatic glucose output, and accelerates lipolysis; the resulting elevation of free fatty acids further aggravates insulin resistance and β-cell dysfunction—a multi-organ pathophysiology described as the "ominous octet" [5]. The net result is chronic hyperglycaemia accompanied by dyslipidaemia.

Chronic hyperglycaemia is the proximate driver of tissue injury. Four principal pathways have been implicated: increased polyol (aldose reductase) pathway flux, enhanced formation of advanced glycation end-products (AGEs) and activation of their receptor (RAGE), activation of protein kinase C (PKC) isoforms, and increased hexosamine pathway flux [6]. Brownlee's unifying hypothesis proposes that all four are driven by a single upstream event—mitochondrial overproduction of superoxide—which links hyperglycaemia to oxidative stress and vascular damage [6,7]. Excess reactive oxygen species deplete antioxidant defences, promote lipid peroxidation, and inactivate protective enzymes such as endothelial nitric oxide synthase, thereby generating the endothelial dysfunction that underlies both microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary, cerebrovascular, peripheral arterial) complications [8].

Landmark trials have confirmed that the magnitude of glycaemic exposure predicts complication risk, and that intensive glucose lowering reduces microvascular disease [9,10]. Understanding the biochemical fingerprint of diabetes—glycaemia, insulin resistance, lipid abnormalities, and oxidative stress—therefore has direct clinical relevance. Accordingly, the present study was designed to characterise and compare these key biochemical markers between T2DM patients and healthy controls, and to explore their interrelationships as a mechanistic basis for diabetic complications.

A hospital-based comparative cross-sectional study was carried out over a six-month period in the Department of Biochemistry of a tertiary-care teaching hospital. The protocol was reviewed and approved by the Institutional Ethics Committee, and written informed consent was obtained from every participant prior to enrolment, in accordance with the Declaration of Helsinki. Study population. A total of 120 adults aged 30–65 years were recruited and divided into two groups: 80 patients with previously diagnosed type 2 diabetes mellitus (diagnosed per American Diabetes Association criteria) and 40 age- and sex-matched apparently healthy non-diabetic controls. Patients with type 1 diabetes, gestational diabetes, acute infection, chronic liver disease, malignancy, thyroid disorders, or a history of smoking or alcohol dependence were excluded, as were individuals on antioxidant supplements, to minimise confounding of oxidative-stress measurements. Sample collection. After an overnight fast of 10–12 hours, 8 mL of venous blood was drawn under aseptic conditions. Samples were distributed into fluoride (for glucose), EDTA (for HbA1c), and plain tubes (for serum separation). Serum was obtained by centrifugation at 3000 rpm for 10 minutes and analysed immediately or stored at −20 °C. A postprandial sample was collected 2 hours after a standard meal, and an early-morning spot urine sample was collected for albumin estimation. Biochemical analyses. Fasting and postprandial plasma glucose were measured by the glucose oxidase–peroxidase (GOD-POD) enzymatic method. HbA1c was determined by immunoturbidimetric/HPLC methods and used to derive estimated average glucose [11]. Fasting serum insulin was assayed by enzyme-linked immunosorbent assay (ELISA), and insulin resistance was calculated using the homeostasis model assessment: HOMA-IR = [fasting insulin (µU/mL) × fasting glucose (mg/dL)] / 405. The lipid profile—total cholesterol, triglycerides, and HDL-cholesterol—was estimated by enzymatic colorimetric methods; LDL-cholesterol and VLDL-cholesterol were derived using the Friedewald equation. Serum creatinine was measured by the modified Jaffe (alkaline picrate) method, and the estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation. Urinary albumin was measured by immunoturbidimetry and expressed as the urinary albumin-to-creatinine ratio (UACR). Oxidative stress markers. Lipid peroxidation was assessed spectrophotometrically as serum malondialdehyde (MDA) by the thiobarbituric-acid reactive substances (TBARS) assay. Antioxidant status was evaluated by measuring reduced glutathione (GSH) using the Ellman (DTNB) method and erythrocyte superoxide dismutase (SOD) activity by the pyrogallol auto-oxidation method. Statistical analysis. All data were entered into and analysed with statistical software. Continuous variables were expressed as mean ± standard deviation (SD). Between-group comparisons were performed using the unpaired Student's t-test, and associations between HbA1c and other parameters were assessed by Pearson's correlation coefficient (r). A two-tailed p-value < 0.05 was considered statistically significant. Note. The tabulated values in the Results section are representative figures consistent with ranges widely reported in the clinical biochemistry literature and are intended to illustrate the expected pattern of findings; they should be replaced with primary laboratory data before use in an actual submission.

Table 1. Demographic and anthropometric characteristics of the study groups

The two groups were comparable in age and sex distribution (p > 0.05), confirming adequate matching. Diabetic patients had significantly higher BMI and waist circumference, reflecting the central adiposity that is strongly associated with insulin resistance and T2DM.

Table 2. Glycemic parameters and insulin resistance

All glycemic indices were markedly elevated in diabetic patients. The near two-fold rise in fasting glucose and the HbA1c of 8.9% indicate poor long-term glycemic control. Elevated fasting insulin together with a high HOMA-IR demonstrates coexisting insulin resistance—the biochemical hallmark of T2DM.

Table 3. Fasting lipid profile

Diabetic patients exhibited the classic atherogenic dyslipidaemia of T2DM: elevated triglycerides, total cholesterol, LDL-C and VLDL-C with reduced HDL-C. This pattern reflects insulin resistance–driven lipolysis, increased hepatic VLDL output, and impaired lipoprotein clearance, and it contributes directly to macrovascular risk.

Table 4. Renal and oxidative stress markers

Elevated serum creatinine, reduced eGFR, and a raised urinary albumin-to-creatinine ratio point to early diabetic nephropathy. The significant rise in MDA indicates increased lipid peroxidation, while the depletion of GSH and SOD reflects an overwhelmed antioxidant defence—together confirming a state of systemic oxidative stress in the diabetic group.

Table 5. Correlation of HbA1c with other biochemical parameters (T2DM group)

HbA1c—an integrated index of chronic glycaemia—correlated positively with oxidative stress (MDA), atherogenic lipids, insulin resistance, and albuminuria, and negatively with antioxidant capacity (SOD) and renal function (eGFR). These correlations link the degree of glycaemic exposure to the biochemical mediators of complications.

This study demonstrates that type 2 diabetes is characterised not by an isolated elevation of blood glucose but by an integrated cluster of biochemical abnormalities—hyperglycaemia, insulin resistance, atherogenic dyslipidaemia, oxidative stress, and early renal impairment—that together provide a mechanistic account of diabetic complications. The significantly raised fasting glucose, postprandial glucose, and HbA1c in patients confirm sustained hyperglycaemia, while elevated fasting insulin and HOMA-IR identify insulin resistance as the central defect underlying impaired glucose disposal and unrestrained hepatic glucose output [4,5]. The atherogenic lipid pattern observed—high triglycerides, LDL-C and VLDL-C with low HDL-C—is consistent with the well-described "diabetic dyslipidaemia." Insulin resistance enhances adipose lipolysis, increasing the free-fatty-acid flux to the liver, which drives VLDL overproduction and, through cholesteryl-ester exchange, generates small dense LDL and low HDL [5]. This lipid phenotype is a major contributor to the accelerated atherosclerosis and macrovascular events seen in diabetes. Our most consistent finding is the marked oxidative imbalance: elevated MDA alongside depleted GSH and SOD. This supports the unifying hypothesis of Brownlee, in which hyperglycaemia-induced mitochondrial superoxide overproduction activates the polyol, AGE/RAGE, PKC, and hexosamine pathways, amplifying reactive oxygen species and depleting antioxidant reserves [6,7]. Oxidative stress inactivates endothelial nitric oxide synthase and prostacyclin synthase, promotes inflammation, and injures the microvasculature, thereby linking glycaemic burden to retinopathy, nephropathy, and neuropathy [8]. The strong positive correlation between HbA1c and MDA, and the inverse correlation with SOD, reinforce this glucose–oxidative stress axis. The renal findings—reduced eGFR and raised urinary albumin-to-creatinine ratio, correlating with HbA1c—are consistent with early diabetic nephropathy driven by the same biochemical pathways acting on the glomerulus. These observations align with landmark interventional evidence. The Diabetes Control and Complications Trial showed that intensive glycaemic control substantially reduces microvascular complications in type 1 diabetes [9], and the UK Prospective Diabetes Study demonstrated comparable benefits in type 2 diabetes, with epidemiological analysis confirming a continuous relationship between glycaemic exposure and complication risk [10]. Antioxidant depletion in our patients further supports the concept that oxidative stress is a causal, rather than merely associative, mediator of tissue damage [8]. Several limitations should be acknowledged. The cross-sectional design precludes causal inference, the sample size was modest and drawn from a single centre, and dietary and treatment variables were not fully controlled. Oxidative-stress assays are also sensitive to sample handling. Nonetheless, the internal consistency of the biochemical pattern—and its agreement with established mechanistic and clinical literature—strengthens the interpretation. Future longitudinal studies incorporating AGE, inflammatory, and genetic markers would clarify the temporal sequence linking glycaemia, oxidative stress, and end-organ injury, and would help identify patients who might benefit from adjunctive antioxidant or lipid-lowering strategies.

Type 2 diabetes mellitus is fundamentally a disorder of integrated metabolic dysregulation. This study shows that chronic hyperglycaemia and insulin resistance are accompanied by atherogenic dyslipidaemia, heightened lipid peroxidation, depleted antioxidant defences, and early renal dysfunction, with HbA1c correlating closely with these downstream abnormalities. The findings illustrate the biochemical continuum that connects poor glycaemic control to the oxidative and vascular processes responsible for diabetic complications. Tight glycaemic control, correction of dyslipidaemia, and reinforcement of antioxidant status therefore represent rational, biochemically grounded targets for preventing or delaying the complications of diabetes. Routine biochemical monitoring—particularly HbA1c, lipid profile, albuminuria, and, where feasible, oxidative-stress indices—can support earlier risk stratification and more individualised management.

1. International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels: International Diabetes Federation; 2025.
2. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S15–33.
3. World Health Organization. Classification of diabetes mellitus. Geneva: World Health Organization; 2019.
4. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806.
5. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–20.
7. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.
8. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.
11. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473–8.
12. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88.
13. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003;26(5):1589–96.
14. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.